Did Danaher beat or miss consensus estimates last quarter?

What were the key takeaways from Danaher’s earnings call?

What is the market's earnings forecast for Danaher next quarter?

What guidance did Danaher's management provide for the next earnings period?

What does Danaher do and what are its main business segments?

What is the revenue and EPS growth rate for Danaher year over year?

What factors drove the changes in Danaher's revenue and profit?

What were the key takeaways from Danaher's earnings call?

- **Q3 Beat**: Core revenue $6.1B (+3%), EPS $1.89 (+10%), free cash flow $1.4B. Bioprocessing (+6.5%) and Diagnostics (+3.5%) led growth.
- **2026 Outlook**: 3-6% core revenue growth, >100bps margin expansion, high single-digit EPS growth. Bioprocessing to drive 60%+ of growth.
- **China Risks**: 2026 assumes $75-100M VBP headwind but improving visibility. Diagnostics ex-China growth accelerating.
- **Cost Actions**: $175M one-time savings ($75M net) to drive $0.30 EPS tailwind. 35-40% EPS fall-through on volume.

**【CEO Summary Section】**
- **Revenue Growth**: Core revenue of $6.1 billion in Q3, up 3% year-over-year, driven by bioprocessing (6.5%) and Diagnostics (3.5%). North America and Western Europe grew mid-single digits, while China declined due to policy headwinds.
- **Segment Performance**: Biotechnology segment grew 6.5% on strong bioprocessing consumables demand. Diagnostics outperformed expectations with respiratory revenue exceeding Q4 prep trends. Life Sciences segment declined 1% due to soft academic demand.
- **Margins and Cash Flow**: Gross margin 58.2%, adjusted operating margin 27.9% (up 40bps). Free cash flow $1.4B, $3.5B year-to-date, with $2B share buybacks.
- **2026 Outlook**: Core revenue growth 3-6%, driven by bioprocessing (high single digits), Diagnostics recovery, and modest Life Sciences improvement. Adjusted EPS growth >100bps margin expansion.

**【CFO Financial Commentary】**
- **Q3 Results**: Adjusted EPS $1.89 (up 10%), exceeding expectations. Non-GAAP EPS $1.08. Free cash flow conversion 146%.
- **2025 Guidance**: Full-year EPS $7.70-$7.80 maintained. Q4 core revenue low single digits, margin ~27% with productivity investments.
- **2026 Cost Actions**: $175M one-time savings ($75M net) to drive $0.30 EPS tailwind. 35-40% EPS fall-through on volume growth.
- **Capital Allocation**: $35M share buyback authorization added to $10M Q3 repurchases. Bias to M&A but open to buybacks at current valuations.

**【Q&A Highlights】**
- **China VBP Impact**: 2026 assumes $75-100M headwind from VBP, but lapping Q4 2025 impacts. Diagnostics ex-China growth expected to accelerate.
- **Bioprocessing Equipment**: Order funnel improving but cautious 2026 equipment spending. Cytiva's $1.5B+ capacity expansion positions for regional manufacturing trends.
- **Respiratory Guidance**: 2026 respiratory revenue $1.7B (same as 2025). Non-respiratory Cepheid growth driven by installed base expansion.
- **Margin Expansion**: 100+bps margin expansion from operating leverage and productivity. 2026 EPS growth >10% before M&A.

Danaher Corporation (DHR) Q3 2025 Earnings Call Transcript

- **Core Growth Resilience**: 1.5% YoY core revenue growth, driven by bioprocessing (6%) and clinical diagnostics (2%).
- **Bioprocessing Momentum**: Low double-digit consumables growth, delayed equipment orders, and high single-digit 2025 guidance reaffirmed.
- **China Market Shifts**: Bioprocessing recovery offsets diagnostics decline, with stimulus-driven demand in tools.
- **EPS Guidance Uptick**: Full-year adjusted EPS raised to $7.70-$7.80, reflecting $150 million cost savings and FX benefits.
- **Respiratory Stability**: $1.7 billion annual target maintained, with 4-in-1 test dominance (75%-80%).

**【CEO Summary Section】**
- **Core Revenue Growth**: 1.5% year-over-year, driven by bioprocessing and clinical diagnostics segments.
- **Bioprocessing Segment**: 6% core revenue growth, with low double-digit growth in consumables and delayed equipment orders due to trade uncertainty.
- **China Market**: Flat overall in high-growth markets, with improvements in bioprocessing and pharma R&D spending offsetting declines in diagnostics.
- **New Product Launches**: Cytiva's MabSelect resins, SCIEX's ZenoTOF 8600, and AstraZeneca partnership for precision medicine diagnostics.
- **Long-Term Outlook**: High single-digit growth expected for bioprocessing, with focus on innovation and cost management.

**【CFO Financial Commentary】**
- **Revenue**: $5.9 billion, with adjusted operating profit margin of 27.3%.
- **Earnings**: Adjusted diluted EPS of $1.80, up 5% year-over-year.
- **Cash Flow**: $1.1 billion free cash flow in Q2, $2.2 billion year-to-date, with 143% conversion ratio.
- **Guidance Update**: Full-year adjusted EPS raised to $7.70-$7.80, reflecting cost savings and FX benefits.
- **Structural Cost Savings**: $150 million target, with half achieved in first half.

**【Q&A Highlights】**
- **Bioprocessing Trends**: Consumables growth (low double digits), equipment delays, and book-to-bill ratio near 1.0.
- **Trade Uncertainty**: Impact on pharma capacity decisions, with expected resolution in 6-12 months.
- **China Recovery**: Improved demand in bioprocessing and pharma, offsetting volume-based procurement declines in diagnostics.
- **Respiratory Business**: $1.7 billion annual guidance maintained, with 75%-80% mix of 4-in-1 tests.
- **Gene Therapy Risk**: Minimal exposure, with genomics revenue focused on plasmids and mRNA for large pharma.


Danaher Corporation (DHR) Q2 2025 Earnings Call Transcript

- **Q1 Strong Start**: Revenue $5.7B, core flat YoY. Bioprocessing +7%, driven by commercialized therapies and new bioreactor launches.
- **Profitability**: Gross margin 61.2% (+100bps), operating margin 29.6% (-50bps) due to cost restructuring.
- **Cash Flow**: $1.1B free cash flow, 110% conversion ratio, despite $350M tariff headwinds.
- **Bioprocessing Momentum**: Orders up 7q in a row, consumables +low double digits, equipment delayed by macro.
- **China Challenges**: Diagnostics -8% due to VBP, offset by non-China growth. Life Sciences -4% due to academic weakness.
- **Guidance**: Full year core +3%, EPS $7.60-$7.75, reflecting tariff mitigation and cautious macro outlook.
- **Tariff Strategy**: Surcharges, supply chain shifts, and regional manufacturing to offset $350M impact.
- **China Long-Term**: View as top 2 Diagnostics market; current pricing aligns with global norms.
- **R&D Resilience**: <10% revenue from pharma R&D tools; bioprocessing >75% in commercial phase.
- **M&A Bias**: Strength in attractive end markets with balance sheet flexibility.


**【CEO Overview】**
- Q1 2025 revenue reached $5.7 billion, with core revenue flat year-over-year. Bioprocessing segment grew 7%, driven by strong demand for commercialized therapies and new product launches like the Xcellerex X-platform bioreactor.
- Gross margin improved to 61.2%, up 100 basis points YoY, due to higher volume leverage and cost management. Adjusted operating margin was 29.6%, down 50 basis points due to structural cost reductions.
- Free cash flow of $1.1 billion resulted in a conversion ratio of over 110%, reflecting strong cash generation despite $350 million in expected tariff headwinds.
- Bioprocessing order book remains robust with sequential growth for seven consecutive quarters, though equipment orders face delays in uncertain macro conditions.
- China's Diagnostics business faced high single-digit declines due to VBP and reimbursement changes, but non-China markets offset this with low single-digit growth.

**【CFO Financial Highlights】**
- Adjusted diluted EPS of $1.88 beat expectations, driven by $420 million GAAP net income and $1.1 billion free cash flow.
- Bioprocessing segment revenue grew 7%, with consumables up low double digits and equipment revenue declining as expected.
- Life Sciences segment core revenue decreased 4%, impacted by weaker academic demand and genomics consumables softness, partially offset by stimulus in China.
- Diagnostics segment core revenue declined 1.5%, with Cepheid's respiratory business exceeding expectations due to elevated illness levels and share gains.
- Full year 2025 guidance: core revenue growth of ~3%, adjusted EPS $7.60-$7.75, reflecting tariff mitigation strategies (surcharges, supply chain adjustments, manufacturing footprint changes).

**【Q&A Key Takeaways】**
- **Bioprocessing Recovery**: Orders grew sequentially for the 7th quarter, with consumables up low double digits. Equipment orders improving but delayed by macro uncertainty. Tariffs not impacting demand yet; Danaher well-positioned with $2B+ capacity investments.
- **Tariff Mitigation**: $350M gross headwind expected, offset via surcharges, supply chain shifts, and manufacturing regionalization. CFO notes all levers (surcharges, cost cuts, footprint changes) are on the table if tariffs worsen.
- **China Strategy**: VBP headwinds in Diagnostics, but patient volumes stable. China stimulus supported Life Sciences instruments in food safety and Tier 2 universities. Long-term view: China will be top 2 Diagnostics market; current pricing aligns with global norms.
- **R&D and Capital Allocation**: <10% of revenue from pharma R&D tools, minimal exposure to potential R&D cuts. Bioprocessing >75% in commercial phase, resilient to macro. M&A bias remains, with balance sheet strength for opportunistic deals in attractive end markets.


Danaher (DHR)-22 Apr 25-2025 Q1 Earnings call transcript

- **2024 Performance**: $23.9B Sales, 1% Q4 Core Growth, $5.3B Free Cash Flow.
- **2025 Outlook**: 3% Core Revenue Growth, 28.5% Margin.
- **Bioprocessing Strength**: 6+ Qs of Order Growth, 6-7% 2025 Guidance.
- **China Risks**: $150M VBP Headwind, Respiratory $1.7B 2025.
- **AI Innovation**: Accelerating R&D, Digital Pathology Partnership.


**【CEO Opening Remarks】**
- 2024 Full-Year Core Revenue: Down 1.5% to $23.9B, with Q4 Core Revenue Growth of 1%.
- Adjusted Operating Margin: 28.6% (flat YoY), Free Cash Flow: $5.3B (135% of Net Income).
- 2025 Outlook: 3% Core Revenue Growth, 28.5% Adjusted Margin.

**【Biotechnology Segment】**
- Q4 Core Revenue Growth: High Single-Digits, Driven by Bioprocessing Consumables.
- Order Book Momentum: 6 Consecutive Qs of High Single-Digit Sequential Growth.
- Equipment Demand: Improved but Capital Spending Remains Cautious.

**【Life Sciences Segment】**
- Q4 Core Revenue: +1%, Instruments Business Outperformed Expectations.
- Genomics Consumables: Declined Due to Protein/Plasmid Market Softness.
- Leica SpectraPlex Launch: Enhances Spatial Biology Capabilities.

**【Diagnostics Segment】**
- Q4 Core Revenue: -2%, Clinical Diagnostics +10% (Biosystems Strength).
- Cepheid Respiratory: $1.7B 2025 Guidance vs. $1.95B 2024.
- China VBP Impact: $150M Headwind vs. Prior $50M/yr Cadence.

**【CFO Financial Highlights】**
- Q4 Sales: $6.5B, Adjusted EPS: $2.14 (+2.4% YoY).
- Share Repurchases: 28M Shares ($7B Deployed) in 2024.
- M&A Activity: Strategic Acquisitions to Strengthen Portfolio.

**【Q&A Key Themes】**
- Life Sciences 2025 Guide: 3% Core Growth, Bioprocessing 6-7%.
- China VBP Risks: Accelerated in Q4, 2025 Headwind of $150M.
- AI Integration: Accelerating R&D Cycles, Digital Diagnostics.
- Bioprocessing Recovery: Order Book Strength, Equipment Caution.


DHR

DHR fundamentals

Earnings Call

You can ask Aime